Vaccines (Sep 2023)

Determinants of Anti-S Immune Response at 12 Months after SARS-CoV-2 Vaccination in a Multicentric European Cohort of Healthcare Workers—ORCHESTRA Project

  • Ludovica Leomanni,
  • Giulia Collatuzzo,
  • Emanuele Sansone,
  • Emma Sala,
  • Giuseppe De Palma,
  • Stefano Porru,
  • Gianluca Spiteri,
  • Maria Grazia Lourdes Monaco,
  • Daniela Basso,
  • Sofia Pavanello,
  • Maria Luisa Scapellato,
  • Francesca Larese Filon,
  • Luca Cegolon,
  • Marcella Mauro,
  • Vittorio Lodi,
  • Tiziana Lazzarotto,
  • Ivan Noreña,
  • Christina Reinkemeyer,
  • Le Thi Thu Giang,
  • Eleonóra Fabiánová,
  • Jozef Strhársky,
  • Marco Dell’Omo,
  • Nicola Murgia,
  • Lucía A. Carrasco-Ribelles,
  • Concepción Violán,
  • Dana Mates,
  • Agripina Rascu,
  • Luigi Vimercati,
  • Luigi De Maria,
  • Shuffield S. Asafo,
  • Giorgia Ditano,
  • Mahsa Abedini,
  • Paolo Boffetta

DOI
https://doi.org/10.3390/vaccines11101527
Journal volume & issue
Vol. 11, no. 10
p. 1527

Abstract

Read online

Background: The effectiveness of the immunity provided by SARS-CoV-2 vaccines is an important public health issue. We analyzed the determinants of 12-month serology in a multicenter European cohort of vaccinated healthcare workers (HCW). Methods: We analyzed the sociodemographic characteristics and levels of anti-SARS-CoV-2 spike antibodies (IgG) in a cohort of 16,101 vaccinated HCW from eleven centers in Germany, Italy, Romania, Slovakia and Spain. Considering the skewness of the distribution, the serological levels were transformed using log or cubic standardization and normalized by dividing them by center-specific standard errors. We fitted center-specific multivariate regression models to estimate the cohort-specific relative risks (RR) of an increase of one standard deviation of log or cubic antibody level and the corresponding 95% confidence interval (CI) for different factors and combined them in random-effects meta-analyses. Results: We included 16,101 HCW in the analysis. A high antibody level was positively associated with age (RR = 1.04, 95% CI = 1.00–1.08 per 10-year increase), previous infection (RR = 1.78, 95% CI 1.29–2.45) and use of Spikevax [Moderna] with combinations compared to Comirnaty [BioNTech/Pfizer] (RR = 1.07, 95% CI 0.97–1.19) and was negatively associated with the time since last vaccine (RR = 0.94, 95% CI 0.91–0.98 per 30-day increase). Conclusions: These results provide insight about vaccine-induced immunity to SARS-CoV-2, an analysis of its determinants and quantification of the antibody decay trend with time since vaccination.

Keywords